All News

The demanding nature of pharmacy programs often leaves little time for self-care, social activities, or hobbies, leading to an imbalance that can foster burnout.

Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.

Though both vaccines remain effective at preventing severe illness, Moderna’s mRNA-1273.222 vaccine was found to be significantly more effective among adults with underlying medical conditions.

The drug is being investigated for its potential to reduce fibrosis associated with muscular dystrophy that can cause scarring of the heart tissue.

The study found that this patient population was about 25% more likely to have serious mental health issues after childbirth.

The nomogram model demonstrated good predictive capabilities to assess progression risk to overt primary myelofibrosis.

The analysis also found that the intervention methods could improve patients’ physical, cognitive, and emotional functioning.

Tripp Logan, PharmD, reflects on being named Independent Pharmacist of the Year from the National Community Pharmacists Association.

Pharmacy teams are learning to adapt to the challenges of limited distribution networks and orphan drug designation in oncology, with integrated pharmacy support playing a crucial role in enhancing patient access and adherence.

RSV vaccines were 80% effective in preventing hospitalization, ICU admission, and death among adults aged 60 years and older.

Children with certain atopic conditions, including asthma and common food allergies, were observed to have a higher risk of developing the chronic disorder.

Efforts include a mandatory intravenous immunoglobulin ordering form, blood bank gatekeeping, and a stewardship committee to ensure optimized use.

Lerodalcibep is a novel, third-generation, anti-PCSK9 therapy small binding protein.

Pharmacists, who play a crucial role at the intersection of prescribing and dispensing, are well-positioned to influence these disparities.

In addition to GLP-1s, dual GLP-1 and GIP agonists, intestinal lipase inhibitors, sympathomimetics, and other agents can help patients lose weight.

Expanding operations to provide specialty infusions can provide benefits to both patients and oncology practices.

Among this population, about 80% had not previously been diagnosed with asthma and over 30% were not using any asthma medications.

Opioid stewardship pharmacist Maureen Saphire, PharmD, BCGP, focuses on advocating for appropriate opioid access for patients with cancer and sickle cell disease, promoting safe opioid use, and supporting leadership and strategic planning as keys to successful opioid stewardship.

New technology and innovation may help turn the corner on antibiotic resistance.

Brian Anderson, PharmD, RPh provides important considerations for pharmacists regarding patient use of benzodiazepines.

Clesrovimab reduced RSV-associated hospitalizations and RSV-associated lower respiratory infection hospitalizations by more than 84% and 90% in preterm and full-term infants, respectively.

Increased bone marrow adiposity is associated with progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma.

Known to be a leading cause of mortality worldwide, cigarette smoke exposure can make the respiratory tract more susceptible to pneumococcal infection.

RBL is the first FDA-approved microbiota-based live biotherapeutic product for adults.

For up to 6 years, cognitive remediation and transcranial direct current stimulation slowed cognitive decline associated with major depressive disorder in remission and mild cognitive impairment.

The authors believe that improvements can be made to overlook the motherhood penalty and its associated pay gaps as well as changes to address workforce burnout.

Trent Thiede, PharmD, president of Pharmacy Audit Assistance Service (PAAS) International, discussed how pharmacy teams can remain prepared for audits from pharmacy benefit managers (PBMs).

Patients with low-grade intermediate-risk non-muscle-invasive bladder cancer who achieved a complete response rate after 3 months of UGN-102 treatment had an 82.3% duration of response at 12 months.